AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39213031 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors identified
Number of subjects: 9672
Study 39213031 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis
Number of subjects: 9672
Study 39213031 — intervention group
Group type: EXPERIMENTAL
Intervention: Urban residents
Number of subjects: 9672
Study 39213031 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR ≥90 mL/min/1.73 m²
Number of subjects: 9672
Study 39213138 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilofexor (100 mg)
Number of subjects: 39
Study 39213138 — intervention group
Group type: EXPERIMENTAL
Intervention: Firsocostat (20 mg)
Number of subjects: 39
Study 39213187 — intervention group
Group type: EXPERIMENTAL
Intervention: Interruption of beta-blocker treatment
Number of subjects: 3698
Study 39213187 — intervention group
Group type: COMPARATOR
Intervention: Continuation of beta-blocker treatment
Number of subjects: 3698
Study 39213194 — intervention group
Group type: EXPERIMENTAL
Intervention: Vutrisiran (25 mg) every 12 weeks for up to 36 months
Number of subjects: 655
Study 39213194 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 655
Study 39213367 — intervention group
Group type: EXPERIMENTAL
Intervention: Optilume drug-coated balloon (DCB)
Number of subjects: 53
Study 39213421 — intervention group
Group type: EXPERIMENTAL
Intervention: Magrolimab plus rituximab (M+R)
Number of subjects: 46
Study 39213738 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Activation Treatment for Anhedonia (BATA)
Number of subjects: 116
Study 39213738 — intervention group
Group type: COMPARATOR
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 116
Study 39213738 — intervention group
Group type: EXPERIMENTAL
Intervention: Both BATA and MBCT
Number of subjects: 116
Study 39213786 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Responders (n=43)
Number of subjects: 522
Study 39213786 — intervention group
Group type: COMPARATOR
Intervention: Late Responders (n=99)
Number of subjects: 522
Study 39213786 — intervention group
Group type: COMPARATOR
Intervention: Stable Disease (n=193)
Number of subjects: 522
Study 39213786 — intervention group
Group type: COMPARATOR
Intervention: Non-Responders (n=187)
Number of subjects: 522
Study 39214018 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Number of subjects: 0
Study 39214018 — intervention group
Group type: COMPARATOR
Intervention: Standard consolidation chemotherapy (SC)
Number of subjects: 0
Study 39214047 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06952229 monotherapy 375 mg, oral b.i.d., 7 days on/7 days off, 28-day cycles (Part 1A)
Number of subjects: 49
Study 39214047 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06952229 monotherapy 375 mg
Number of subjects: 49
Study 39214047 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06952229 monotherapy
Number of subjects: 49
Study 39214047 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06952229
Number of subjects: 49
Study 39214106 — intervention group
Group type: EXPERIMENTAL
Intervention: Capivasertib-fulvestrant
Number of subjects: 901
Study 39214106 — intervention group
Group type: COMPARATOR
Intervention: Placebo-fulvestrant
Number of subjects: 901
Study 39214467 — intervention group
Group type: EXPERIMENTAL
Intervention: Bepirovirsen 300 mg once weekly for 24 weeks followed by Peg-IFN 180 μg once weekly for up to 24 weeks (Arm 1)
Number of subjects: 108
Study 39214467 — intervention group
Group type: EXPERIMENTAL
Intervention: Bepirovirsen 300 mg once weekly for 12 weeks followed by Peg-IFN 180 μg once weekly for up to 24 weeks (Arm 2)
Number of subjects: 108
Study 39214467 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy with bepirovirsen followed by Peg-IFN
Number of subjects: 108
Study 39214467 — intervention group
Group type: COMPARATOR
Intervention: Bepirovirsen alone
Number of subjects: 108
Study 39214650 — intervention group
Group type: EXPERIMENTAL
Intervention: Eganelisib combined with atezolizumab and nab-paclitaxel
Number of subjects: 11
Study 39214650 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral blood analyses
Number of subjects: 11
Study 39214801 — intervention group
Group type: EXPERIMENTAL
Intervention: Milvexian 100 mg twice daily
Number of subjects: 15500
Study 39214801 — intervention group
Group type: COMPARATOR
Intervention: Apixaban (5 mg or 2.5 mg per label indication) twice daily
Number of subjects: 15500
Study 39214886 — intervention group
Group type: EXPERIMENTAL
Intervention: Nike Advanced Footwear Technology Spikes (NAS)
Number of subjects: 21
Study 39214886 — intervention group
Group type: COMPARATOR
Intervention: Control condition (SS)
Number of subjects: 21
Study 39214920 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous bermekimab 400 mg in Study 1
Number of subjects: 329
Study 39214920 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous bermekimab 400 mg qw or every 2 weeks in Study 2
Number of subjects: 329
Study 39214920 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous bermekimab 350 mg or 700 mg qw in GENESIS
Number of subjects: 329
Study 39214920 — intervention group
Group type: COMPARATOR
Intervention: Intravenous bermekimab 800 mg qw in LUNA
Number of subjects: 329
Study 39215063 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g of dark chocolate
Number of subjects: 20
Study 39215063 — intervention group
Group type: COMPARATOR
Intervention: 7.5 g of milk chocolate
Number of subjects: 20
Study 39215063 — intervention group
Group type: EXPERIMENTAL
Intervention: dark chocolate
Number of subjects: 20
Study 39215063 — intervention group
Group type: COMPARATOR
Intervention: milk chocolate
Number of subjects: 20
Study 39215149 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviorally informed electronic letter-based nudges
Number of subjects: 881373
Study 39215149 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 881373
Study 39215196 — intervention group
Group type: EXPERIMENTAL
Intervention: Transepidermal water loss (TEWL)
Number of subjects: 384
Study 39215196 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin pH
Number of subjects: 384
Study 39215196 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratum corneum hydration (SCH)
Number of subjects: 384
Study 39215196 — intervention group
Group type: EXPERIMENTAL
Intervention: Sebum content
Number of subjects: 384
Study 39215253 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontitis group
Number of subjects: 90
Study 39215253 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 90
Study 39215257 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiving Management Needs Scale (CMNS)
Number of subjects: 250
Study 39215274 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Application Group (SAG) - one piezocision before canine retraction
Number of subjects: 30
Study 39215274 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Application Group (MAG) - three piezocisions over 12 weeks
Number of subjects: 30
Study 39215274 — intervention group
Group type: COMPARATOR
Intervention: Control (contralateral sides of both groups)
Number of subjects: 30
Study 39215289 — intervention group
Group type: EXPERIMENTAL
Intervention: Stannous fluoride dentifrice (SnF)
Number of subjects: 40
Study 39215291 — intervention group
Group type: EXPERIMENTAL
Intervention: Haptotherapeutic Well-Being Scale
Number of subjects: 242
Study 39215293 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate (MTA)
Number of subjects: 63
Study 39215293 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodentine
Number of subjects: 63
Study 39215293 — intervention group
Group type: EXPERIMENTAL
Intervention: MMP-2 and MMP-9 expression levels
Number of subjects: 63
Study 39215301 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary total elbow replacement (TER)
Number of subjects: 0
Study 39215323 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronidase (150 IU)
Number of subjects: 60
Study 39215323 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg)
Number of subjects: 60
Study 39215323 — intervention group
Group type: COMPARATOR
Intervention: Control (contralateral sides)
Number of subjects: 60
Study 39215351 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06817024
Number of subjects: 0
Study 39215351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39215367 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheal intubation-associated cardiac arrest (TI-CA)
Number of subjects: 315
Study 39215367 — intervention group
Group type: COMPARATOR
Intervention: Non-tracheal intubation-associated cardiac arrest (non-TI-CA)
Number of subjects: 315
Study 39215531 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan (Sac/Val) therapy
Number of subjects: 376
Study 39215531 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker (control)
Number of subjects: 376
Study 39215646 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Dose Quadrivalent Influenza Vaccine
Number of subjects: 0
Study 39215646 — intervention group
Group type: COMPARATOR
Intervention: Standard-Dose Quadrivalent Influenza Vaccine
Number of subjects: 0
Study 39215793 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MA) 160 mg orally daily
Number of subjects: 36
Study 39215793 — intervention group
Group type: COMPARATOR
Intervention: Levonorgestrel-intrauterine system (LNG-IUS)
Number of subjects: 36
Study 39215793 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MA and LNG-IUS
Number of subjects: 36
Study 39215812 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study 39215812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39215861 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 88
Study 39215861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 39215872 — intervention group
Group type: EXPERIMENTAL
Intervention: Carnosine (2 g/day)
Number of subjects: 0
Study 39215872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39215949 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimekizumab 160 mg every 4 weeks
Number of subjects: 1032
Study 39215949 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab 40 mg every 2 weeks (control group in BE OPTIMAL)
Number of subjects: 1032
Study 39215959 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin monotherapy
Number of subjects: 5833
Study 39215959 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel monotherapy
Number of subjects: 5833
Study 39215972 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight potassium control (supplementing if serum potassium concentration fell below 4.5 mEq/L)
Number of subjects: 1690
Study 39215972 — intervention group
Group type: COMPARATOR
Intervention: Relaxed potassium control (supplementing if serum potassium concentration fell below 3.6 mEq/L)
Number of subjects: 1690
Study 39215972 — intervention group
Group type: COMPARATOR
Intervention: Relaxed potassium control
Number of subjects: 1690
Study 39215972 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight potassium control
Number of subjects: 1690
Study 39216091 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity CRP
Number of subjects: 27939
Study 39216091 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL cholesterol
Number of subjects: 27939
Study 39216091 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipoprotein(a)
Number of subjects: 27939
Study 39216093 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter edge-to-edge repair (intervention group)
Number of subjects: 210
Study 39216093 — intervention group
Group type: COMPARATOR
Intervention: Surgical mitral-valve repair or replacement (surgery group)
Number of subjects: 210
Study 39216095 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 455
Study 39216095 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 455
Study 39216096 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of oral anticoagulation
Number of subjects: 858
Study 39216096 — intervention group
Group type: COMPARATOR
Intervention: Interruption of oral anticoagulation
Number of subjects: 858
Study 39216092 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter mitral-valve repair and guideline-recommended medical therapy (device group)
Number of subjects: 505
Study 39216092 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone (control group)
Number of subjects: 505
Study 39216107 — intervention group
Group type: EXPERIMENTAL
Intervention: Garetosmab 10 mg/kg every 4 weeks for 28 weeks
Number of subjects: 41
Study 39216107 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 39216107 — intervention group
Group type: EXPERIMENTAL
Intervention: Garetosmab
Number of subjects: 41
Study 39216464 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive lacosamide (LCM) treatment
Number of subjects: 905
Study 39216478 — intervention group
Group type: EXPERIMENTAL
Intervention: ESG401 (Trop2 antibody-drug conjugate) at a maximum tolerated dose of 16 mg/kg on days 1, 8, and 15 of a 28-day cycle
Number of subjects: 40
Study 39216478 — intervention group
Group type: EXPERIMENTAL
Intervention: ESG401 (Trop2 antibody-drug conjugate) at therapeutically relevant doses
Number of subjects: 40
Study 39216619 — intervention group
Group type: EXPERIMENTAL
Intervention: Reorientation of care (Group 1)
Number of subjects: 165
Study 39216619 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Group 2)
Number of subjects: 165
Study 39216726 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 0
Study 39216726 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids
Number of subjects: 0
Study 39217247 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm cycle ergometry training (ACET)
Number of subjects: 16
Study 39217247 — intervention group
Group type: COMPARATOR
Intervention: Body weight-supported treadmill training (BWSTT)
Number of subjects: 16
Study 39217271 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital consults (DCs)
Number of subjects: 150
Study 39217271 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 150
Study 39217292 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction Competencies with Children - for Teachers (ICC-T) and Interaction Competencies with Children - for Parents (ICC-P)
Number of subjects: 16
Study 39217292 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 16
Study 39217447 — intervention group
Group type: EXPERIMENTAL
Intervention: Aficamten
Number of subjects: 0
Study 39217448 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgical aortic valve replacement (AVR)
Number of subjects: 157
Study 39217448 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (watchful waiting)
Number of subjects: 157
Study 39217450 — intervention group
Group type: EXPERIMENTAL
Intervention: mavacamten
Number of subjects: 231
Study 39217453 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg once daily
Number of subjects: 46
Study 39217453 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 39217504 — intervention group
Group type: EXPERIMENTAL
Intervention: Zibotentan (10 mg daily for 12 weeks)
Number of subjects: 118
Study 39217504 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 39217550 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 2255
Study 39217550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2255
Study 39217553 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 1 mg once-weekly subcutaneous injection
Number of subjects: 3533
Study 39217553 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3533
Study 39217557 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiology-guided complete revascularization
Number of subjects: 1445
Study 39217557 — intervention group
Group type: COMPARATOR
Intervention: Culprit-only revascularization
Number of subjects: 1445
Study 39217556 — intervention group
Group type: EXPERIMENTAL
Intervention: Aficamten (5-20 mg daily for 24 weeks)
Number of subjects: 282
Study 39217556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 282
Study 39217559 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 2.4 mg
Number of subjects: 17604
Study 39217559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17604
Study 39217563 — intervention group
Group type: EXPERIMENTAL
Intervention: Aficamten (5-20 mg for 24 weeks)
Number of subjects: 50
Study 39217563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 39217564 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 2.4 mg once weekly
Number of subjects: 1145
Study 39217564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1145
Study 39217567 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide (2.4 mg once weekly)
Number of subjects: 1145
Study 39217567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1145
Study 39217565 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 2.4 mg once weekly
Number of subjects: 1145
Study 39217569 — intervention group
Group type: EXPERIMENTAL
Intervention: Aficamten
Number of subjects: 282
Study 39217569 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 282
Study 39217570 — intervention group
Group type: EXPERIMENTAL
Intervention: GMRx2 ¼ dose (telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg)
Number of subjects: 295
Study 39217570 — intervention group
Group type: EXPERIMENTAL
Intervention: GMRx2 ½ dose (telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg)
Number of subjects: 295
Study 39217570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 295
Study 39217573 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin monotherapy
Number of subjects: 926
Study 39217573 — intervention group
Group type: COMPARATOR
Intervention: No antiplatelet therapy
Number of subjects: 926
Study 39217577 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 4795
Study 39217577 — intervention group
Group type: COMPARATOR
Intervention: Valsartan
Number of subjects: 4795
Study 39217605 — intervention group
Group type: EXPERIMENTAL
Intervention: GP IIb/IIIa inhibitors (eptifibatide or tirofiban)
Number of subjects: 120
Study 39217605 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy without GP IIb/IIIa inhibitors
Number of subjects: 120
Study 39217617 — intervention group
Group type: EXPERIMENTAL
Intervention: BP-EES
Number of subjects: 239
Study 39217617 — intervention group
Group type: COMPARATOR
Intervention: DP-EES
Number of subjects: 239
Study 39217615 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation screening enhanced by NT-proBNP; NT-proBNP concentrations measured, single-lead ECG registered once if NT-proBNP <125 ng/L, prolonged screening if NT-proBNP ≥125 ng/L.
Number of subjects: 13905
Study 39217615 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screening).
Number of subjects: 13905
Study 39217615 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation screening enhanced by NT-proBNP.
Number of subjects: 13905
Study 39217615 — intervention group
Group type: EXPERIMENTAL
Intervention: Low NT-proBNP group (NT-proBNP <125 ng/L).
Number of subjects: 13905
Study 39217777 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 0
Study 39217809 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon beta-1a (125 µg subcutaneous every two weeks)
Number of subjects: 168
Study 39217809 — intervention group
Group type: COMPARATOR
Intervention: Interferon beta-1a (30 µg intramuscular once a week)
Number of subjects: 168
Study 39217809 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon beta-1a
Number of subjects: 168
Study 39217809 — intervention group
Group type: COMPARATOR
Intervention: Interferon beta-1a
Number of subjects: 168
Study 39217809 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 168
Study 39217835 — intervention group
Group type: EXPERIMENTAL
Intervention: Looking at a dog (VISUAL)
Number of subjects: 33
Study 39217835 — intervention group
Group type: EXPERIMENTAL
Intervention: Petting a dog (TACTILE)
Number of subjects: 33
Study 39217835 — intervention group
Group type: EXPERIMENTAL
Intervention: Performing tricks with a dog (ACTIVE)
Number of subjects: 33
Study 39217835 — intervention group
Group type: COMPARATOR
Intervention: No dog present (CONTROL)
Number of subjects: 33
Study 39218041 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-fraction preoperative partial breast irradiation (PBI) 20 Gy
Number of subjects: 13
Study 39218164 — intervention group
Group type: EXPERIMENTAL
Intervention: Multitarget stool DNA test
Number of subjects: 3453
Study 39218164 — intervention group
Group type: EXPERIMENTAL
Intervention: FIT OC-SENSOR
Number of subjects: 3453
Study 39218164 — intervention group
Group type: EXPERIMENTAL
Intervention: FIT FOB-Gold
Number of subjects: 3453
Study 39218164 — intervention group
Group type: EXPERIMENTAL
Intervention: Stool-based post-polypectomy surveillance strategies
Number of subjects: 3453
Study 39218164 — intervention group
Group type: EXPERIMENTAL
Intervention: Multitarget stool DNA-based surveillance
Number of subjects: 3453
Study 39218164 — intervention group
Group type: EXPERIMENTAL
Intervention: FIT-based surveillance
Number of subjects: 3453
Study 39218222 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic OXPHOS capacity
Number of subjects: 65
Study 39218222 — intervention group
Group type: EXPERIMENTAL
Intervention: FPG ≤100 mg/dl
Number of subjects: 65
Study 39218222 — intervention group
Group type: EXPERIMENTAL
Intervention: FPG >100 mg/dl
Number of subjects: 65
Study 39218222 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver lipid content threshold value of 24%
Number of subjects: 65
Study 39218222 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of prediabetes
Number of subjects: 65
Study 39218222 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of MASLD
Number of subjects: 65
Study 39218222 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing liver lipid contents and plasma glucose concentrations
Number of subjects: 65
Study 39218222 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolically active drugs
Number of subjects: 65